TNF inhibition as therapy for rheumatoid arthritis.
(2002) In Expert Opinion on Investigational Drugs 11(7). p.947-953- Abstract
- The introduction of TNF- alpha -inhibiting biologicals has been a major therapeutic breakthrough in rheumatoid arthritis therapy. Against a background of conventional disease-modifying antirheumatic drug experience, this review focuses on present experiences and possible future developments. TNF inhibition results in profound improvement in the majority of rheumatoid arthritis patients, but non-response and adverse effects need attention. Adalimumab is being filed for approval. Other monoclonal antibodies or receptor constructs are in late development. Small molecule inhibitors of TNF production or signalling are a hot topic. One emerging target is nuclear factor kappa B and selective inhibition has proved effective in animal models of... (More)
- The introduction of TNF- alpha -inhibiting biologicals has been a major therapeutic breakthrough in rheumatoid arthritis therapy. Against a background of conventional disease-modifying antirheumatic drug experience, this review focuses on present experiences and possible future developments. TNF inhibition results in profound improvement in the majority of rheumatoid arthritis patients, but non-response and adverse effects need attention. Adalimumab is being filed for approval. Other monoclonal antibodies or receptor constructs are in late development. Small molecule inhibitors of TNF production or signalling are a hot topic. One emerging target is nuclear factor kappa B and selective inhibition has proved effective in animal models of arthritis. Synovial proliferation in rheumatoid arthritis is characterised by diminished apoptosis of fibroblasts, whereas bone marrow precursor cells undergo accelerated apoptosis in active rheumatoid arthritis. Both abnormalities are seemingly ameliorated by TNF inhibition. Anti-apoptotic strategies will soon go into development for control of unresponsive rheumatoid arthritis. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/109015
- author
- Wollheim, Frank LU
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Expert Opinion on Investigational Drugs
- volume
- 11
- issue
- 7
- pages
- 947 - 953
- publisher
- Ashley Publications
- external identifiers
-
- wos:000176675900005
- pmid:12084005
- scopus:0035986898
- pmid:12084005
- ISSN
- 1744-7658
- DOI
- 10.1517/13543784.11.7.947
- language
- English
- LU publication?
- yes
- id
- cba388f5-e5b3-4e3b-bbd1-89bdb03ca290 (old id 109015)
- alternative location
- http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12084005&dopt=Abstract
- date added to LUP
- 2016-04-01 11:34:10
- date last changed
- 2022-01-26 07:09:16
@article{cba388f5-e5b3-4e3b-bbd1-89bdb03ca290,
abstract = {{The introduction of TNF- alpha -inhibiting biologicals has been a major therapeutic breakthrough in rheumatoid arthritis therapy. Against a background of conventional disease-modifying antirheumatic drug experience, this review focuses on present experiences and possible future developments. TNF inhibition results in profound improvement in the majority of rheumatoid arthritis patients, but non-response and adverse effects need attention. Adalimumab is being filed for approval. Other monoclonal antibodies or receptor constructs are in late development. Small molecule inhibitors of TNF production or signalling are a hot topic. One emerging target is nuclear factor kappa B and selective inhibition has proved effective in animal models of arthritis. Synovial proliferation in rheumatoid arthritis is characterised by diminished apoptosis of fibroblasts, whereas bone marrow precursor cells undergo accelerated apoptosis in active rheumatoid arthritis. Both abnormalities are seemingly ameliorated by TNF inhibition. Anti-apoptotic strategies will soon go into development for control of unresponsive rheumatoid arthritis.}},
author = {{Wollheim, Frank}},
issn = {{1744-7658}},
language = {{eng}},
number = {{7}},
pages = {{947--953}},
publisher = {{Ashley Publications}},
series = {{Expert Opinion on Investigational Drugs}},
title = {{TNF inhibition as therapy for rheumatoid arthritis.}},
url = {{http://dx.doi.org/10.1517/13543784.11.7.947}},
doi = {{10.1517/13543784.11.7.947}},
volume = {{11}},
year = {{2002}},
}